Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sol-Gel Technologies Ltd. specializes in developing and commercializing innovative dermatological products, particularly in the treatment of acne and skin diseases. The company leverages its proprietary formulation technology to create high-margin products that differentiate it from competitors in the biotechnology space.
Sol-Gel generates revenue primarily through the sale of its dermatological products, which are marketed under various brand names. The company's competitive advantages include a unique formulation technology that enhances product efficacy and reduces side effects, allowing for premium pricing. Additionally, its strong intellectual property portfolio protects its innovations.
FDA approval of new dermatological products
Partnerships with larger pharmaceutical companies for distribution
Clinical trial results impacting product efficacy and safety
Market penetration rates in key geographies such as the U.S. and Europe
Regulatory changes impacting drug approval processes
Technological disruption in drug formulation and delivery
Emergence of generic competitors for existing products
Increased competition from larger pharmaceutical companies with more resources
Negative operating cash flow could limit future R&D investment
Low revenue base increases vulnerability to market fluctuations
low - The demand for dermatological products is relatively inelastic, as consumers prioritize healthcare and personal care regardless of economic conditions.
Minimal impact, as the company has low debt levels (Debt/Equity of 0.02), reducing sensitivity to financing costs.
minimal
growth - Investors are likely attracted to the potential for high revenue growth from innovative products.
high - The stock has shown significant volatility, with a 1-year return of 132.6%.